Mutual fund houses have been offering a free add-on feature of life insurance cover to investors who invest through SIPs of select mutual fund schemes. The amount of life insurance cover offered depends on the amount of monthly SIP investment made by the investor, so higher the SIP amount, higher the life insurance cover. 

A travel insurance policy should not only cover the risk of death and hospitalisation, but it should also provide cover for delay or cancellation in flight, baggage loss, etc arising during travel.

Need for diversification or high growth makes savvy investors dabble in illiquid securities. Some want to transact in tax-free bonds, fixed maturity plans (FMP), closed-ended funds (CEF) or even non-convertible debentures (NCD) listed on stock exchanges. 

There are literally thousands of brokers in India offering not just stockbroking services, but also many other kinds of financial products and services to their clients. So, how does one decide on which brokerage house to choose and what criteria should be applied?

With the markets going into correction and consolidation mode, the year 2018 has been disappointing for the mid-cap and small-cap fund investors. These funds have corrected more than the large-cap funds and investors in these funds are clueless about their next course of action.

Rites Limited, a Government company, is coming with an IPO which will open for subscription from June 20 to June 22, 2018. The issue consists of Offer for Sale (OFS) of 2,52,00,000 equity shares worth Rs 466.20 crores. The issue price band is between Rs 180-185 per equity share.

In the recent past, the mutual fund houses aligned their products to invest in the pharma sector. The sector which has seen a huge decline in the last couple of years is now a darling for the mutual fund houses. Recently, Mirae Assets and ICICI Pru announced new thematic schemes keenly focused on maximizing profits from the pharma sector stocks.

The company signed an agreement with Indorama Group to exit their joint venture company, Egyptian Indian Polyester Company (EIPET).

Following stocks are close to their 52-week low as at 12.43 p.m. on June 15, 2018.

Dr. Reddy's Laboratories has received final approval from the US drug regulator for launching Buprenorphine and Naloxone Sublingual Film in the US market. The product is being launched through an approved Risk Evaluation and Mitigation Strategy (REMS) Program.